Gazyva Wins FDA Approval for Childhood-Onset Nephrotic Syndrome, Giving Families a New Option to Reduce Relapses
The FDA approved Gazyva on Sept. 25 to reduce relapse risk in patients 2 years and older with childhood-onset nephrotic syndrome. Here is what families should know.
Medical Daily ·